Evidence map›Paper›PMID 26138828›Full record

ArticleJournal of hematology & oncology2015

Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation.

Luis F Porrata, David J Inwards, Stephen M Ansell, Ivana N Micallef, Patrick B Johnston, William J Hogan, Svetomir N Markovic

Open access · goldAbstract read
In one paragraph

Article in Journal of hematology & oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Luis F PorrataDivision of Hematology, Department of Medicine, Mayo Clinic, 200 first St. SW, Rochester, MN, 55905, USA. porrata.luis@mayo.edu.
David J InwardsDivision of Hematology, Department of Medicine, Mayo Clinic, 200 first St. SW, Rochester, MN, 55905, USA.
Stephen M AnsellDivision of Hematology, Department of Medicine, Mayo Clinic, 200 first St. SW, Rochester, MN, 55905, USA.
Ivana N MicallefDivision of Hematology, Department of Medicine, Mayo Clinic, 200 first St. SW, Rochester, MN, 55905, USA.
Patrick B JohnstonDivision of Hematology, Department of Medicine, Mayo Clinic, 200 first St. SW, Rochester, MN, 55905, USA.
William J HoganDivision of Hematology, Department of Medicine, Mayo Clinic, 200 first St. SW, Rochester, MN, 55905, USA.
Svetomir N MarkovicDivision of Hematology, Department of Medicine, Mayo Clinic, 200 first St. SW, Rochester, MN, 55905, USA.
Mayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe infused autograft lymphocyte-to-monocyte ratio (A-LMR) is a prognostic factor for survival in B-cell lymphomas post-autologous peripheral hematopoietic stem cell transplantation (APHSCT). Thus, we set out to investigate if the A-LMR is also a prognostic factor for survival post-APHSCT in T-cell lymphomas.

methodsFrom 1998 to 2014, 109 T-cell lymphoma patients that underwent APHSCT were studied. Receiver operating characteristic (ROC) and area under the curve (AUC) were used to identify the optimal cut-off value of A-LMR for survival analysis and k-fold cross-validation model to validate the A-LMR cut-off value. Univariate and multivariate Cox proportional hazard models were used to assess the prognostic discriminator power of A-LMR.

resultsROC and AUC identified an A-LMR ≥ 1 as the best cut-off value and was validated by k-fold cross-validation. Multivariate analysis showed A-LMR to be an independent prognostic factor for overall survival (OS) and progression-free survival (PFS). Patients with an A-LMR ≥ 1.0 experienced a superior OS and PFS versus patients with an A-LMR < 1.0 [median OS was not reached vs 17.9 months, 5-year OS rates of 87% (95% confidence interval (CI), 75-94%) vs 26% (95% CI, 13-42%), p < 0.0001; median PFS was not reached vs 11.9 months, 5-year PFS rates of 72% (95% CI, 58-83%) vs 16% (95% CI, 6-32%), p < 0.0001].

conclusionsA-LMR is also a prognostic factor for clinical outcomes in patients with T-cell lymphomas undergoing APHSCT.

Indexed as

AdultAgedAutograftsCohort StudiesFemaleHematopoietic Stem Cell TransplantationHumansLymphocytesLymphoma, T-CellMaleMiddle AgedMonocytesPeripheral Blood Stem Cell TransplantationPrognosisSurvival AnalysisTransplantation, Autologous

Identifiers

PMID26138828
PMCPMC4490710
OpenAlexW1504825220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.